Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03353753 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
A Phase 3 study, sponsored by Deciphera Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 129
- Enrollment target
NCT03353753 is a Phase 3 study that has completed, run by Deciphera Pharmaceuticals. The registered enrollment target is 129 participants.
The verdict
NCT03353753, a Phase 3 study, has completed, sponsored by Deciphera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 129 participants
- Enrollment target
Study Summary
This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients were randomized in a 2:1 ratio to ripretinib 150 mg QD or placebo
Interventions
- DRUG Placebo Oral Tablet
- DRUG DCC-2618
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2022-05-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03353753
The ClinicalTrials.gov registry entry for NCT03353753 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03353753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03353753 about?
NCT03353753 is a clinical study titled "Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies". This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib, and regoraf...
What is the current status of trial NCT03353753?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 129 participants. The study started on 2018-02-27. Estimated completion is 2022-05-11.
What interventions are being tested in trial NCT03353753?
The interventions under investigation include: Placebo Oral Tablet (DRUG), DCC-2618 (DRUG).
Who is sponsoring clinical trial NCT03353753?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.